Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
-
ARCHIVE Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
-
ARCHIVE Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Peptisyntha to Expand Contract Peptide Manufacturing Business in Japan
September 3, 2007
-
ARCHIVE Drugs Account for 21.7% of Medial Expenditure
September 3, 2007
-
ARCHIVE DSP to Increase Its MRs' Scientific Knowledge
September 3, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Wholesalers' Operating Profit Ratio Exceeds 1% for the 1st Time in 8 Years
September 3, 2007
-
ARCHIVE Enuresis Causes Stress in Over 70% of Children and Parents
September 3, 2007
-
ARCHIVE Japanese Companies Are at Greater Risk of Takeover than US, European Companies: Mr Ota
September 3, 2007
-
ARCHIVE Daiichi Sankyo Healthcare to Launch Japan's First Drug to Improve Chloasma
September 3, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Contributing to Personalized Medicine through PGx: Third Wave Japan
September 3, 2007
-
ARCHIVE Korosho to Conduct Studies to Introduce CU System
September 3, 2007
-
ARCHIVE Asian Regulatory Conference to Focus on Multinational Trials, GRP
September 3, 2007
-
ARCHIVE Korosho Approves 35 New Drugs, New Indications
September 3, 2007
-
ARCHIVE Industry's Drug Pricing System Reform Proposals Incompatible with Current System: Mr Tsushima
September 3, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 3, 2007
-
ARCHIVE Korosho to Create Council for Promotion of Generics in Each Prefecture
September 3, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…